



Zosano Pharma  
Investor Relations Department  
34790 Ardentech Ct.  
Fremont, CA 94555  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

#### NASDAQ: ZSAN

|               |                            |
|---------------|----------------------------|
| Last Trade:   | 1.28                       |
| Trade Time:   | 4:00 PM ET<br>Jul 27, 2017 |
| Change:       | -0.02  (-1.538%)           |
| Day Range     | 1.25 - 1.32                |
| 52-Week Range | 0.45 - 3.54                |
| Volume        | 202,806                    |

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Zosano Pharma is an emerging CNS company focusing on providing rapid symptom relief to patients, using known therapeutics with well-established safety and efficacy, but altering their delivery profile using the Company's proprietary transdermal delivery system. The Company's goal is to make transdermal drug delivery a standard of care for delivering drugs requiring fast onset of action.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*Jun 26, 2017*

[Zosano Pharma Announces Outcome of End of Phase 2 Meetings with FDA](#)

*Jun 14, 2017*

[Zosano Announces Inducement Grants under NASDAQ Listing Rule 5635\(c\)\(4\)](#)

*Jun 12, 2017*

[Zosano Presents Additional Data from ZOTRIP Study at American Headache Society, Demonstrating Positive Results for Pain Freedom and Sustained Pain Freedom](#)

*Jun 1, 2017*

[Zosano to Present Migraine Data at Three Industry-Leading Conferences](#)

*May 9, 2017*

[Zosano Reports First Quarter 2017 Financial Results and Announces Management Changes](#)

## Financials [\[ View all \]](#)

*Mar 1, 2017*

[Annual Report \(10-K\)](#)

*Apr 28, 2017*

[Proxy Statement \(DEF 14A\)](#)

*May 9, 2017*

[Quarterly Report \(10-Q\)](#)

*Nov 9, 2016*

[Quarterly Report \(10-Q\)](#)

*Aug 10, 2016*

[Quarterly Report \(10-Q\)](#)